A systematic review of genetic studies of thyroid disorders in Taiwan identified studies of gene mutations involved in the synthesis and binding of thyroid hormone, as well as mutations of proto-oncogenes and tumor suppressor genes in thyroid cancer. Studies related to gene polymorphisms in patients with autoimmune thyroid disease (AITD) and thyroid cancer were also reviewed. The most prevalent mutations in the Han-Chinese population were c.2268insT in the thyroid peroxidase (TPO) gene and c.919-2A>G in the Pendred syndrome (PDS ) gene. Additional mutations have also been revealed in the genes encoding TPO (n ¼ 5), thyroglobulin (TG; n ¼ 6), pendrin (n ¼ 2), and thyroxinebinding globulin (TBG; n ¼ 2), which were novel at the time they were reported. The prevalence of various somatic mutations in differentiated thyroid cancer was similar in Taiwan and Western countries, with the RAS kinase mutation and tyrosine receptor kinase (TRK ) and rearranged during transfection (RET ) proto-oncogenes being detected in lower frequencies and the B-type RAF kinase (BRAF ) mutation accounting for the majority of cases. Recent microRNA analysis revealed an association between miR146b and the BRAF mutation, which was associated with poor prognosis of papillary thyroid carcinoma (PTC). Susceptibility to Graves' disease (GD) was linked to the human leukocyte antigen (HLA) region. The associated alleles were different in Han-Chinese and Caucasians; HLA-DPB1*0501, the major allele in Taiwan, has a low frequency in the West. By contrast, a high frequency of HLA-DRB1*0301 was detected in Caucasians but not Han-Chinese. In addition to the HLA region, cytotoxic T lymphocyte-associated molecule-4 (CTLA4) gene polymorphisms þ49G>A and þ6230G>A (CT60) were positively associated with GD. The GG genotype and G allele of single nucleotide polymorphism (SNP) þ49G>A were also related to relapse of Graves' hyperthyroidism after antithyroid drug withdrawal. Differences in the genetic patterns between Han-Chinese and Caucasians for some thyroid disorders suggest the importance of variable genetic influences in different populations.
Introduction
Thyroid disorders may be categorized into two general groups, including functional disorders such as hyperthyroidism and hypothyroidism, and structural abnormalities, including goiter and thyroid neoplasia. The basis of some thyroid disorders may reflect the effect of a mutation in a single gene (e.g., monogenic) or the effects of polymorphisms in multiple genes. Among the monogenic diseases, germline mutations can affect thyroid hormone synthesis or thyroid hormone binding in serum. However, somatic mutations play a major role in thyroid neoplasia pathogenesis. Impaired synthesis of thyroid hormone may result in congenital hypothyroidism while mutations in the genes encoding thyroid hormone carrier proteins lead to clinically euthyroid patients with falsely abnormal thyroid function tests. In addition, an increased risk for autoimmune thyroid disease (AITD) or thyroid neoplasia has been associated with genetic polymorphisms at various loci (Fig. 1) . The current review will summarize the results of major genetic studies performed in Taiwan regarding thyroid disorders to provide a basis for further understanding of the thyroid genetics in the HanChinese population.
Genetic basis of congenital hypothyroidism
The prevalence of congenital hypothyroidism in Taiwan ranges from 1 in 1992 live births to 1 in 5788 live births, 1, 2 which is similar to the 1 in 4000 live births reported in European and North American populations. 3, 4 Thyroid dysgenesis, such as agenesis, hypoplasia, ectopy, and hemiagenesis, accounts for 80e85% of congenital hypothyroidism; thyroid dyshormonogenesis contributes to the remaining 15e20% of cases. 5, 6 Congenital hypothyroidism may be the result of impaired thyroid stimulating hormone (TSH) signaling, abnormal thyroid hormone synthesis, or defective thyroid hormone action in target tissues (Fig. 2) . 6 The majority of genetic studies in Taiwan have focused on germline mutations involving the thyroid hormone synthesis pathways, such as pendrin for the trapping of iodide into thyroid follicular cells, and thyroid peroxidase (TPO), which regulates iodide organification by binding iodide to thyroglobulin (TG) and further coupling to form thyroxine (T4) and triiodothyronine (T3). 7e9 The severity of thyroid dyshormogenesis is based on whether there is a total or partial defect in the organification of iodide. Mutation in the TPO gene is the major contributing factor for total iodide organification defect (TIOD); mutation in the Pendred syndrome (PDS ) gene usually causes partial iodide organification defect (PIOD). 7, 10 Despite an intact thyroid hormone synthesis pathway in the thyroid follicular cells, synthesis of thyroid hormone remains impaired in the absence of a signal from pituitary thyroid stimulating hormone (TSH) to a functional thyroid TSH receptor. Loss-of-function mutations in the TSH receptor gene may induce TSH resistance and subsequent congenital hypothyroidism. 11 Mutations in the thyroid hormone receptor alpha and beta have been reported to result in impaired thyroid hormone action in target tissues; however, we failed to identify any study in Taiwan regarding this issue. 12 
TPO
The human TPO gene consists of 17 exons and spans about 150 kilobases on chromosome 2p25. 14, 15 In the study by Niu et al 7 that evaluated 16 patients from 16 unrelated Taiwanese families with thyroid dyshormogenesis, seven patients were classified as having TIOD, and two patients had PIOD as detected by the perchlorate discharge test. Three mutations, including c.2268insT, c.2243delT, and p.G157C, in the TPO gene were identified in the seven patients with TIOD; no TPO gene mutation was detected in the two patients with PIOD. 7 In another study from Taiwan, five TPO gene mutations, including c.2268insT, c.843delC, c.2413delC, c.1477G>A, and c.2386G>T, were detected in five unrelated patients with TIOD. 8 All of the above mutations identified in Taiwanese patients had not been detected in other ethnic groups at the time of the report, suggesting the heterogenic nature of TPO mutations by ethnicity. The c.2268insT mutation was found to be the most common mutation observed in both studies, accounting for 86% (12/14) of the mutant alleles in the report from Niu et al 7 and 40% (4/10) of the studied alleles in Wu et al. 8 A thymidine (T) insertion in exon 13 of the 2268 residue of the TPO gene may lead to a premature stop codon, resulting in the formation of truncated polypeptides and dysfunctional TPO enzymes. 7, 8 In addition to being the cause of congenital hypothyroidism, c.2268insT was also associated with transient hypothyroidism of the neonate. 16 Haplotype analysis revealed that the c.2268insT mutation in Taiwan may be due to a founder effect. 7 
PDS
The PDS gene, also known as SLC26A4, contains 21 exons expanding 57,174 base pairs on chromosome 7q22-q31. 1. 17e19 This gene encodes the pendrin protein, an anion transporter expressed in the thyroid, kidney, and inner ear. Pendred syndrome (PS) is an autosomal recessive disorder caused by biallelic mutations in the PDS gene, manifesting as congenital sensorineural deafness, goiter, partial iodine organification defect, and thyroid dysfunctions, ranging from euthyroid to hypothyroidism. 10 High heterogeneity and differences by ethnicity were noted in the PDS mutations. Huang et al 20 recently summarized the mutation spectrum of the SLC26A4 gene in the Chinese population. Although the great majority of mutations found worldwide were missense mutations, a single splice-site mutation of c.919-2A>G (g.IVS7-2A>G) was reported to account for > 80% of the mutations observed in Taiwan. 21e23 Following c.919-2A>G, c.2168A>G (p. H723R) was the second most common mutation in HanChinese. 20 By contrast, the p.L236P, p.T416P, IVS8þ1G>A, p.E384G, p.L445W, p.T410M, p.G209V, p.V138F, p.Y530H, and p.L597S mutations were more commonly detected in Caucasians. 20 In another study from Taiwan by Lai et al, 23 a missense mutation of c.1079C>T (p.A360V) in exon 9 of the SLC26A4 gene was discovered for the first time in 2007. Huang et al 20 later identified another new splice-site mutation of c.1263þ1G>A (g.IVS10þ1G>A) in compound heterozygosity with c.1079C>T in a Taiwanese patient with PS.
TG
Human TG is encoded by a large gene of 270 kilobases that maps to chromosome 8q24 and contains a coding sequence of 8.5 kilobases divided into 48 exons. 24 Mutations in the TG gene may result in congenital hypothyroidism, goiter, thyroid neoplasia, or familial AITD. 25 In seven Taiwanese patients from six families with a TG defect, six new TG gene mutations, including c.1348delT, p.R432X (c.1351C>T), g.IVS3þ2T>G, c.1712delT, p.Q1765X (c.5350C>T), and c.6047delA, were identified, which all led to a premature translation termination. 9 The most common mutations were c.1348delT and p.R432X. 9 The high prevalence of c.1348delT was thought to be due to a founder effect by linking to a specific haplotype, and p.R432X was due to an independently recurrent de novo mutation, suggesting a mutational hot spot. 9 
TSH receptor mutation
The human TSH receptor gene is located on chromosome 14q31 and encodes the G-protein-coupled TSH receptor from exons one to 10. 9 Autonomous thyroid adenoma or congenital hyperthyroidism may develop as a result of gain-of-function mutations, and loss-of-function mutations in the TSH receptor gene are the most common cause of TSH resistance. 26 Systematic analysis of the TSH receptor gene in Japanese patients with congenital hypothyroidism revealed a particularly prevalent variant c.1349G>A (p.R450H) as the cause of loss-of-function TSH receptor mutations. 27 This mutation was also shown to be important in Taiwanese children with congenital hypothyroidism. 28 
Genetic alterations affecting thyroid hormone binding
The physiologically active forms of the thyroid hormones, free T4 and free T3, account for around 0.3% of the circulating thyroid hormones; the remaining 99.7% are bound to carrier proteins, including thyroxine-binding globulin (TBG; 70%), albumin (15e20%), and transthyretin (10e15%). Patients with carrier protein gene mutations are clinically euthyroid but laboratory abnormal and are often misdiagnosed as having thyroid dysfunction. 29, 30 In patients with familial dysalbuminemic hyperthyroxinemia (FDH), serum albumin exhibits increased binding affinity to T4, causing free T4 and total T4 concentrations to be elevated as detected by the one-step analog method but normal using the equilibrium dialysis or two-step methods. 31, 32 In TBG deficiency, a low concentration of total T4 and total T3 may result in the misdiagnosis of hypothyroidism if free T4 was not measured simultaneously or subsequently, resulting in unwarranted treatment with antithyroid drug or thyroid hormone replacement. 30 
FDH
The human albumin gene is located within q11-22 of chromosome 4 and contains 15 exons split by 14 intervening sequences. 33 The molecular basis of FDH relates to a point mutation in codon 218 of the albumin gene, which causes a substitution of histidine (CAC) or proline (CCC) for arginine (CGC). 34, 35 The first Chinese case of FDH with guanine (G) to adenosine (A) transition in the second nucleotide of codon 218 of the albumin gene was reported in 1999. 29 This missense mutation is the same as that described frequently in Western white families, but differs from the one found in a Japanese kindred analysis. 34, 35 3.2. TBG deficiency TBG is encoded by the TBG gene on Xq22 chromosome and consists of five exons spanning 5.5 kbp.
36,37 TBG anomalies are transmitted through an X-linked fashion and produce the following three clinical phenotypes determined by the serum levels of TBG: complete TBG deficiency, partial TBG deficiency, and TBG excess. 38, 39 Complete TBG deficiency is caused by either early termination of translation or an amino acid substitution, resulting in secretion failure. 40, 41 In the report by Su et al, 30 two TBG gene mutations, which were novel at that time, were discovered in two cases of complete TBG deficiency in Taiwan. In one case, a missense mutation, p.S52N, consisting of a G to A transition in codon 52, resulted in the substitution of serine (AGC) for asparagine (AAC). In the other case, a nonsense mutation, p.W280X, consisting of a G to A transition in codon 280 (TGG/TGA) resulted in premature termination of translation and therefore, a truncated protein. 30 
Somatic mutations in thyroid cancer
Thyroid cancers arising from thyroid epithelial cells include the differentiated thyroid cancers papillary thyroid carcinoma (PTC), follicular carcinoma, and poorly differentiated carcinoma, and the undifferentiated thyroid cancer anaplastic thyroid carcinoma (ATC). PTC and follicular carcinoma account for > 90% of thyroid cancers and generally carry a favorable prognosis with 10-year survival rates of 93% and 85%, respectively. 42 By contrast, patients with ATC have a median survival of < 6e8 months. 43 Our current understanding of the molecular pathogenesis of thyroid cancer resulted from identification of genetic and epigenetic alterations in various signaling pathways, including the mitogen activated protein kinase (MAPK), the phosphatidylinositol-3 kinase (PI3K)eprotein kinase (AKT), the nuclear factor-kB (NF-kB), the Ras association domaincontaining protein 1 (RASSF1)-mammalian sterile 20 (STE20)-like protein kinase 1 (MST1)eforkhead box O3 (FOXO3), the WNT-b-catenin, the hypoxia-inducible factor 1a (HIFIa), and the TSH receptor pathways. 44 Among the various pathways, the MAPK and PI3KeAKT are the pathways best characterized and show promise in thyroid cancer treatment. 45 Activation of the MAPK pathway mainly drives the development of PTC. 44 By contrast, activation of the PI3KeAKT pathway is involved in the formation of follicular adenoma and carcinoma. 44 Upon simultaneous activation of both pathways with an accumulation of genetic alterations, PTC or follicular carcinoma may progress to poorly differentiated carcinoma or anaplastic carcinoma. 44 
Mutations involving the MAPKePI3KeAKT pathway
MAPKePI3KeAKT signaling is essential for maintaining cell growth, proliferation, differentiation, and apoptosis (Fig. 3) . 46 Approximately 70% of cases of PTC are related to somatic mutations involving the RET/PTC/RAS/-BRAF/mitogen extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. 44, 47 Rearrangement of two receptor tyrosine kinase genes, rearranged during transfection (RET ) and neurotrophic tyrosine kinase receptor type 1 (NTRK1), are specifically expressed in PTC. 48, 49 The frequency of RET/PTC rearrangement ranges from 55% (n ¼ 6/11) as reported by Lee et al 50 to 8% (n ¼ 8/105) in Liu et al. 51 After comparing its prevalence, which ranges from 0% to 20% worldwide, 52e54 we think that the RET/PTC may not be as common as previously reported by Lee et al. 50 Moreover, the chimeric gene resulting from NTRK1 rearrangement, the TRK proto-oncogene, was not detected in 40 thyroid tumors isolated from patients in Taiwan, suggesting that the prevalence of TRK mutation is even lower than RET/PTC rearrangement in Taiwan. 51, 55 In a study of 89 thyroid tumors, four RAS mutations were detected in follicular carcinoma (n ¼ 3) and follicular adenoma (n ¼ 1); however, they were absent in the papillary carcinomas analyzed, suggesting that its occurrence differs by tumor type. 56 In contrast to the low occurrence of RET/PTC rearrangement and the TRK and RAS mutations in Taiwan, the BRAF mutation was reported to be the most prevalent mutation in PTCs and found exclusively in thyroid cancers arising from papillary cells. 47, 57, 58 The heterozygous mutation c.T1799A (p.V600E) in exon 15 of the BRAF gene was detected in 49 of 105 (47%) sporadic cases of PTC in Taiwan, 57 which was a similar frequency to that reported from other geographical areas.
59e61 Recent meta-analysis suggested a positive correlation between BRAF mutation and high-risk clinicopathological features of PTC, such as extrathyroid invasion, lymph node metastasis, and advanced tumor stage. 62 However, inconsistency exists in the literature, 47 and no correlation was found in a study conducted in Taiwan. 57 Recent studies on microRNA deregulation have demonstrated an association of specific microRNAs, particularly miR-146b, with the aggressiveness and prognosis of PTC, 63, 64 which may be related to increased cell proliferation, migration, invasion, or resistance to chemotherapy-induced apoptosis in response to aberrant microRNA expression. 64 
Mutations outside the MAPK pathway
In addition to mutations related to the MAPK pathway, other genetic alterations have been postulated to have a role in the pathogenesis of thyroid cancer, including those affecting the p53, phosphatase and tensin homolog (PTEN ), and fragile histidine triad protein (FHIT ) genes. 65e67 It is understood that p53 suppresses growth in normal cells; its inactivation is associated with colon, lung, breast, and thyroid cancer development. 68 In Taiwan, mutations in the p53 gene have been detected in five of 29 (17.2%) cases of poorly differentiated carcinomas, two of 41 (5.0%) cases of welldifferentiated papillary carcinoma, and one of six (16.7%) cases of oncocytic carcinoma of the thyroid. 65 Consistent with the results of other reports, the p53 gene mutations identified included single nucleotide changes, resulting in missense or nonsense mutations.
Germline mutations in the PTEN tumor suppressor gene occur often in Cowden syndrome, a syndrome characterized by multiple tumor-like harmatomas and an increased risk of certain cancers, such as breast, endometrial, and thyroid follicular carcinomas. 69 However, somatic mutation of the PTEN gene was not found in any of the 17 sporadic thyroid tumors studied in Taiwan, indicating that the PTEN gene may not play a major role in sporadic thyroid tumors. 66 With complete sequencing of the FHIT gene, deletions between exons 2 and 9 were found in seven cases of thyroid tumors in Taiwan, suggesting that FHIT gene alterations may have a role in the formation of thyroid neoplasm. 67 
Mutation analysis in anaplastic thyroid carcinoma
Mutation analysis of 16 anaplastic thyroid carcinoma patients in Taiwan revealed five (5/16, 31%) cases with an N-RAS mutation and one (1/16, 6%) case with a BRAF mutation. 70 While the current understanding is that accumulation mutations in both the MAPK and PI3KeAKT pathways may result in anaplastic thyroid carcinoma, this disease may arise more often from RAS-mutant tumors than from BRAF-mutant tumors. 70 
Genetics of medullary thyroid carcinoma
Medullary thyroid carcinomas (MTCs) derive from parafollicular calcitonin-producing C-cells originating from the neural crest. 71 MTC is a type of neuroendocrine tumor that possesses distinct clinical and pathological characteristics from differentiated thyroid cancers. 71 The genetic basis of MTC is different from that of the differentiated thyroid cancers due to its association with multiple endocrine neoplasia (MEN) and familial MTC syndrome. 72 Mutations in the RET proto-oncogene were detected in > 95% of patients with MTC with MEN type 2 (MEN-2), but the frequency dropped to around 50% in sporadic MTCs. 72 Consistent with the results reported for Western countries, mutation analysis of the RET proto-oncogene in sporadic and MEN-associated MTC in Taiwan revealed two common mutation sites at codon 634, causing a substitution of cysteine to arginine or phenylalanine (p.C634R, p.C634Y), and at codon 918, resulting in methionine to threonine replacement (p.M918T). 73e75 Furthermore, in cytomorphology analysis of MTCs using fine needle aspiration specimens, codon 634 mutations were more strongly associated with small/round or large/oval to polygonal cells, while codon 918 mutations were more related to small/round and spindle shape cells. 75 
Polymorphism studies in thyroid cancer
In Taiwan, gene polymorphisms of the vascular endothelial growth factor (VEGF ) gene, genes of the BER (base excision repair) pathway, and the glutathione peroxidase 3 (GPX3) gene have been studied in thyroid cancer.
76e79 VEGF acts through the transmembrane fms-like tyrosine kinase (FLT) receptor family to influence cell proliferation, migration, and angiogenesis; it also plays an important role in thyroid cancer cell growth and distant metastasis. 76 Analysis of functional single nucleotide polymorphisms (SNPs) of VEGF in Taiwan disclosed that the A allele of K2578C/A (i.e., SNP rs699947) was associated with an increased risk of thyroid cancer and regional lymph node metastasis in men. 77 Alterations in genes associated with the BER pathway, one of the DNA repair pathways, are also hypothesized to have a role in carcinogenesis. 78 The X-ray repair cross complementing one (XRCC1) gene, especially the 194Trp allele, as well as a functional polymorphism of one of the BER genes, were related to thyroid cancer development and progression in Taiwan. 78 Moreover, gene polymorphism of the antioxidant enzyme GPX3 has also been analyzed; the C allele of rs8177412 was suggested to confer an increased risk for the development of differentiated thyroid cancer as compared to the T allele of rs8177412. 79 6. Genetic predisposition to AITD
Susceptible loci in the human leukocyte antigen region
Genetic predisposition to AITD has been linked to a susceptible gene locus in the human leukocyte antigen (HLA) region and in non-HLA regions, including the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), CD40, protein tyrosine phosphatase-22 (PTPN22), TG, and thyroid stimulating hormone receptor (TSHR) genes in Caucasians. 80 Linkage analysis revealed a positive association between Graves' disease (GD) and the HLA region in a Taiwanese population. 81 HLA-DR2 and DR9 were the first two associated alleles found. 82 HLA-B*4601, the predominant allele across Asian countries, was also reported to be a susceptible allele for both GD and Hashimoto thyroiditis (HT) in Taiwan. 83, 84 Other dominant genes in different populations included HLA-A*0207 in adult GD patients and HLA-DRB1*0901 in children with GD. 83, 85 More comprehensive HLA genotyping performed recently in Taiwan identified susceptible alleles with independent effects, including HLA-B*4601, HLA-DPB1*0501, DRB1*1502, and 1602. 84 Specifically, whereas DRB1*1202 and DQB1*0302 conferred a protective effect for GD, a high frequency of HLA-DRB1*0301 was detected in Caucasians with GD, and HLA-DPB1*0501 was shown to be the major allele associated with GD in Taiwan. 84 
CTLA-4 gene in GD
CTLA-4 functions as a T cell regulator, inhibiting T cell activation possibly through interfering with the costimulatory effect of CD28. 86 Meta-analysis of CTLA-4 gene polymorphisms has showed a positive association of two SNPs, þ49G>A and þ6230G>A (CT60), with AITD. 86 In a Taiwanese population, the GG genotype and G allele of SNP CT60 was associated with susceptibility to GD in adults and children. 87, 88 Besides the association with GD, the GG genotype and G allele of SNP þ49G>A was also related to relapse of Graves' hyperthyroidism after withdrawal of antithyroid drugs. 89, 90 Similar to the antigen presentation and T cell activation function of major histocompatibility complex (MHC), MHC class I-chain related gene A (MICA) functions as a stress-induced antigen and ligand for natural killer (NK) cell activation. 91 Microsatellite repeat polymorphism within the transmembrane region of MICA varied between individuals. 91 In children with GD, Lo et al 91 found that allele A5 was associated with higher risk for the development of GD.
Cytokine gene polymorphism and AITD
Association-related studies of cytokine gene polymorphism in AITD are discrepant. 92e100 In Taiwan, a positive association with GD was found in the allelic variants of the interleukin-1-b (IL-1-b) gene promoter (G-511C) and the tumor necrosis factor-a (TNF-a) gene promoter (G-238A and G-308A), but not the IL-1 receptor antagonist (IL-1RA) gene, the IL-8 3 0 untranslated region (3 0 -UTR), or the IL-4, IL-6, and IL-10 gene promoters. 93e96 In addition, a meta-analysis of eight studies by Lee et al 97 reported no association between IL-4 gene SNPs and GD. However, a TA haplotype of the IL-4 gene conferred risk for GD, suggesting that the haplotype-based method may be more powerful in studying geneedisease associations than individual SNPs. 97 
Other studies on HT
The number of genetic studies on HT was much lower than that of GD in Taiwan. In addition to the aforementioned positive association of HLA-B*4601 with HT, the C/G genotype and allele C of SNP rs187238 in the IL-18 gene conferred an increased risk in children. 98 Analysis of four common polymorphisms of the vitamin-D receptor (VDR) gene, including FokI (rs10735810), TaqI (rs731236), BsmI (rs1544410), and ApaI (rs7975232), suggested that the homozygous C/C VDR-FokI gene polymorphism in exon 2 conferred a higher risk of developing HT in Chinese patients. 99 However, a recent meta-analysis suggested that the BsmI and TaqI polymorphisms were more strongly associated with AITD, whereas ApaI or FokI polymorphisms were not. 100 In conclusion, the mutation spectrum of the Han-Chinese population observed in monogenic thyroid disorders was different from that of Caucasians. The single most common mutation in the TPO gene, c.2268insT, was observed in more than half of the cases of congenital hypothyroidism with TPO gene mutation in Taiwan. In the PDS gene, IVS7-2A>G (c.919-2A>G) accounted for > 80% of the mutations in the Han-Chinese population. All of the six mutations identified in the TG gene were novel, suggesting that there may be a distinct mutation spectrum in the Taiwanese population. By contrast, the epidemiology of different somatic mutations in differentiated thyroid cancer in Taiwan was similar to that of Western countries, with most of the mutations involving the MAPK pathway in a prevalent sequence of BRAF occurring more often than RAS, RET/PTC, and TRK mutations. In sporadic and MEN-associated MTC in Taiwan, two common mutation sites in the RET proto-oncogene at codons 634 and 918 were observed, which is consistent with results from other populations.
In genetic studies of AITDs, different dominant HLA alleles in Asians or Caucasians with GD were disclosed; HLA-DPB1*0501 was found in high frequency in Asian countries but not in the West. In addition, two SNPs of the CTLA-4 gene, þ49G>A and þ6230G>A (CT60), were positively associated with GD in Taiwan. Analysis of cytokine genes in Taiwan as well as in other populations has been conflicting.
Thus, local genetic studies of thyroid disorders in Taiwan suggest that specific genetic patterns exist in some diseases in Han-Chinese whereas others were similar to the results observed worldwide.
